dcsimg Aranesp® (darbepoetin alfa) – Hemoglobin (Hb) Trends
› Email› Print

The nephrology landscape continues to evolve
Mean quarterly Hb levels in 2011 and 20131

Mean quarterly Hb levels in 2011 and 2013

For patients with CKD on dialysis

  • Initiate Aranesp® treatment when the Hb level is < 10 g/dL.
  • Individualize dosing and use the lowest dose of Aranesp® sufficient to reduce the need for RBC transfusions.

Important Safety Information

WARNING - Chronic Kidney Disease:

  • In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL
  • No trial has identified a hemoglobin target level, Aranesp® dose, or dosing strategy that does not increase these risks.
  • Use the lowest Aranesp® dose sufficient to reduce the need for red blood cell (RBC) transfusions.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; RBC = red blood cell; Hb = hemoglobin.
Reference: 1. Data on file, Amgen; [OutcomesPlus database; July 2013].

Biotechnology by Amgen®